Advancements in Targeting the Androgen Receptor Pathway in Prostate Cancer : Episode 2

Opinion

Video

February 19, 2024

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

Author(s):

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice

EP: 1.Metastatic Prostate Cancer: Background and Patient Prognosis

Now Viewing

EP: 2.Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

EP: 3.Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

EP: 4.Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

EP: 5.Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

EP: 6.Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

EP: 7.Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Related Content

December 11th 2024

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer

July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

December 5th 2024

FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer

June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Capivasertib Plus Abiraterone/ADT in PTEN-Deficient mHSPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 25th 2024

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer